AUTHOR INDEX

Abercrombie, D. M. 209
Allen, R. A. 333
Arvela, P. 157

Back, P. 153
Blachley, J. D. 435
Bock, K. W. 23
Bock-Hennig, B. S. 23
Boobis, A. R. 101
Breckenridge, A. 95
Brockmeyer, N. H. 205
Buchet, J. P. 193

Cadenas, E. 179
Caldwell, J. 79
Chaiken, I. M. 209
Champion, G. D. 383
Cochrane, C. G. 333
Combs, G. F. Jr 303
Combs, S. B. 303

Damanhouri, Z. 145
Datema, R. 221
Davies, D. S. 101
Day, R. O. 383
De Bruijn, E. A. 171
de Jager, J. 383
Desager, J. P. 197
Dive, C. 193
Dumont, E. 193, 197

Eichelbaum, M. 201
Epping, J. 163

Fischer, G. 23
Fonne, R. 19
Fournel, S. 79

Geubel, A. P. 193
Graham, G. G. 383
Gugler, R. 133

Harvengt, C. 197
Hawes, E. M. 73
Heidemann, H. 205
Herbert, S. A. 145
Heusler, H. 163
Hoensch, H. 121
Horowitz, Z. D. 317

Ivanetich, K. M. 85

Jaiswal, A. K. 11
Jensen, J. C. 133, 201
Jesaitis, A. J. 333
Joeres, R. 163
Jorgensen, L. 83

Kirch, W. 129
Klinger, W. 55
Klinker, H. 163
Klotz, U. 157
Knochel, J. P. 435
Kroemer, H. 157

Lilienblum, W. 23
Loos, U. 201

Magdalou, J. 79
Mansuy, D. 41
McGirr, L. G. 63
McKay, G. 73
McManus, M. E. 47
Meyer, U. A. 19
Midha, K. K. 73
Moldeus, P. 37
Moore, G. J. 349
Morton, H. G. 449
Murray, S. 101
Musch, E. 201

Nebert, D. W. 11
Netter, K. J. 1
Nicholls, P. J. 145

O'Brien, P. J. 63
Oesch, F. 29
Ohnhaus, E. E. 205
Olofsson, S. 221

Park, B. K. 109
Pasanen, M. 157
Pauwels, S. 193
Pelkonen, O. 115, 157
Perucca, E. 139
Poulson, H. E. 83

Quanguan, Jiang 37

Remmer, H. 89
Richter, E. 163
Romero, F. J. 179
Romero, P. A. 221
Roy, S. D. 73

Samuels, H. H. 317
Schirmer, G. 23
Schladt, L. 29
Schwabe, H. K. 201
Seddon, C. E. 101
Siest, G. 79
Smith, D. A. 187
Sotaniemi, E. A. 115
Subrahmanyam, V. V. 63
Thomsen, P. 83
Thumser, A. E. A. 85
Tjaden, U. R. 171
Van Oosterom, A. T. 171
Williams, K. M. 383
Witzemann, V. 287

SUBJECT INDEX

2-Acetylaminofluorene
  cytochrome oxidation 47–52
  metabolites 49
    drug effects 50, 51
    hydroxy derivatives 52
N-Acetyl(p)benzoquinone imine, toxicity 38, 39
Adenosine nucleotide transporter 298, 299
  nucleotide affinity 293
  photoaffinity labeling 287–99
ADP/Fe^{2+}-induced lipid peroxidation 183
ADP/Fe^{2+}-promoted chemiluminescence 184
Adverse drug reactions, non-steroidal anti-inflammatory drugs 402–14
Affinity labeling 349 *see also* photoaffinity
Age and antipyrene *N*-demethylation 187–90
Alcohol *see also* ethanol
  enzyme induction and inhibition 117, 118
Aminoglutethimide
  O-demethylation 149, 150
  endoplasmic reticulum 149, 150
  estradiol activity 148
  hexobarbitone-induced hypnosis 147, 148
  liver effects 151
  oxidative drug metabolism inducer 145–52
  structure 145
δ-Aminolevulinic acid synthetase induction 56, 57
Aminopyrene *N*-demethylation
  age and tumors in mice 187–90
Angiotensin *see also* receptor
  angiotensin-mediated contraction 369
  concentration–effect curves 368
  microelectronic effects 374
  II and III and receptor photoaffinity labeling 355–59
Antibiotics
  macrolide and cytochrome P-450 41–45
    drug interactions 44, 45
    structure 42
Antiepileptic drugs, liver microsome induction 139–44
Antigens, HBsAg carriers
  aminopyrene breath test 194, 195
  cytochrome P-450 193–95
Antiviral sugar analogs 232–37
  dolichol pathway 234
Aryl hydrocarbon hydrolase induction 57, 58
ATP
  neuronal function 287, 288
  neurotransmitter co-storage 288–91
  uptake and neurotransmitter 291–93

Bromoconduritol structure and glucosidase inhibition 241, 242
Bufuralol, cytochrome oxidation 47–52

Caffeine
  elimination and mexiletine 163–68
  pharmacokinetics 165, 166
Calcium deficiency
  ethanol effects 441–43
  treatment 442, 443
Cancer
  induction effects 89–93
  and P-450 gene family 14
Chemicals, occupational 118, 119
Chemiluminescence 179
  and glutathione in hepatocytes 182
Cholestasis, phenobarbital 153–55
Cimetidine
  and metabolism 129
  oxidative metabolism 130, 131
Cyclophosphamide
  ethanol and metabolism 171–76
  metabolism 171
  pharmacokinetic data 174, 175
Cytochrome P-450
  HBsAg carriers 193–95
  human liver microsomal 47–52
  isoenzyme induction 19–21
  macrolide antibiotics 41–45
  TAO derivative induction 44

Debrisoquine
  metabolism and smoking 102
  oxidation 47–52
Debrisoquine 4-hydroxylase 102, 103
  K_i value 104
1-Deoxynojirimycin
  glucosidase inhibition 244
  structure 241
Diazepam
  omperazole interaction 134
  oral contraceptive interactions 133
Disulfiram, acetaminophen hepatotoxicity 83
Drug conjugation tests 111
Drug interactions, NSAIDs 414–17
Drug metabolism
  glutathione 37–40
  oxygen activation 63–72
  polymorphism 11–15
Drug oxidation tests 109–11

Environmental tests
  co-administered drug effects 97, 98
  toxic induced 98
Epoxide hydrolase, coordinate induction 29–34
Erythralosamine derivatives 43
Ethanol
  abuse and drug metabolism 126
  acute effects 122–24
  biochemical effects 121
  calcium effects 441–43
  chronic effects 123
  cyclophosphamide interaction 171–76
  drug metabolism 124–26
  enzyme induction and inhibition 117, 118, 121–27

hypophosphatemia 436, 437
magnesium effects 439, 440
plasma effects 435
skeletal muscle effects 443–46
urine effects 435
7-Ethylcoumarin, dealkylation inhibition 136
Ethylene dibromide, GSH S-transferases 85–88
interactions 88

Glucosidase inhibitors 241–46
structure 241
Glutathione (GSH)
drug metabolism 37–40
peroxidase-mediated oxidation 67, 68
protection 38
reactive intermediates 37
Glycoproteins, viral
herpes simplex, properties 264
oligosaccharides *see also* oligosaccharides
biosynthesis 224–32
inner cores 222
structure 221–24
types 223
processing inhibitors 240–50
sugar analogs 232–37
tunicamucin 237, 238
Glycosylation
inhibitor effects 250–70
inhibitor structures 239
GSH *S*-transferases
inhibitor model 87
reversible inhibition 85–88

H_2-receptor antagonists *see also* cimetidine, ranitidine
diazepam interactions 159, 160
doses 158
enzymes inhibited 160, 161
in vivo and *in vitro* drug metabolism 157–61
oxidative metabolism inhibition 129–31
structures 158
Hepatic mixed function oxidase, 6β-hydroxycortisol excretion 197–99
Hormones, anticonvulsant interactions 141, 142
6β-Hydroxycortisol
and antipyrene clearance 198
excretion and mixed function oxidase 197–99

Induction
cancer effects 89–93
clinical aspects 95–99
conjugating enzymes 23–26
coordinate 29–34
cytochrome P-450 isoenzymes 19–21
developmental aspects 55–60
drug–drug interactions 95
drug oxidation 101–107
environmental factors 115–19
hormonal control 59, 60
in vivo study 109–12
monooxygenase 1–9
old age 58, 59
stereospecificity 79–82
time-course 112
toxicity 96, 97
variability 96
Inhibition
clinical importance 113–36
conjugating enzymes 25, 26
cytochrome P-450 8
developmental aspects 55–60
drug oxidation 101–107
environmental aspects 115–19
in vivo study 109–12
monooxygenase 6–9
protein glycosylation 221–72
reversible 85–88
Liver disease, environmentally induced 118, 119

Magnesium deficiency
alcohol effects 439–41
treatment 440, 441
Mannosidase inhibitors 246–48
structure 242
Methoxyphenamine
oxidative metabolism 73
metabolites 75
Methoxyphenamine *O*-demethylase, activity and inhibition 73–76
Met-tyr-*p*-azido-pheamide synthesis 211, 212
Mexiletine
caffeine elimination 163–68
cardiac arrhythmias 163, 164
pharmacokinetics 165, 166
Monooxygenase
induction and inhibition 1–9
mechanism 3
3-methylcholanthrene 1, 2
salt effects 104
sulmazole induction 5, 6

Neurophysins
amino acid composition 217
hormone binding surface 216, 217
photolabeled properties 215, 216
Neurotransmitter, cholinergic and ATP 288–93
Nojirimycin
glucosidase inhibition 242–44
structure 241
Non-steroidal anti-inflammatory drugs (NSAID)
adverse effects 402–14
gastrointestinal 402–406
age 401, 402
anaphylaxis 411, 412
bleeding disorders 410, 411
chemical properties 384, 385
clinical pharmacology 383–418
CNS effects 412, 413
doses 405
drug interactions 414–17
elimination half-life 393–98
hematological effects 413, 414
hepatotoxicity 409, 410
liver disease effects 399, 400
metabolism 398
overdose 413
pH and cellular accumulation 384
plasma protein binding 389–91
renal excretion 400, 401
renal toxicity 406–409
risk factors 408, 409
responders 388, 389
skin reactions 412
stereoselectivity 399
synovial fluid 391–93
variability in response 385–402
pharmacodynamics 386–88
pharmacokinetics 388–402

Oligosaccharide biosynthesis
assembly 228, 229, 231
blood group A reactive 231
dolichol pathway 226
inhibitors 232–40
N-linked 224–30
O-linked 230
pathways 225–27
β-Oxidation activity
coordinate induction 29–34
drug effects 34
inducers 31
inducibility 33
scheme 30
temperature 32
Oxygen activation
drug metabolism 63–72
thiyl radical formation 65
Oxygen uptake stimulation 66
Oxytocin, photoaffinity labeling 209–17

P-450 gene superfamily 11–12
and cancer 14, 15
regulation 13
P-4501 gene family 12–14
Paraquat toxicity and selenium 305
Pharmacodynamic analysis 173
Pharmacokinetic analysis 172, 173
Phenobarbital
bile acid disappearance 154
cholestasis use 153–55
Phenobarbital induction, cytochrome P-450 19–21
2-Phenylpropionic acid
enantiomers 80, 81
HPLC separation 80
three dimensional structure 79
Phenytoin, omperazole interaction 135
Phosphorus deficiency
cellular injury 438
and ethanol 436, 437
treatment 438, 439
Photoaffinity labeling
adenosine nucleotide transporter 287–99
angiotensin receptors 239–79
chemical affinity comparison 328–30
concept 349
covalent modification 215
dose–response curves 352–54
N-formyl peptide receptors 333–47
neurophysin, specificity 212–15
neurophysin structure 217, 218
oxytocin and vasopressin 209–18
spare receptors 354, 355
thyroid hormone receptors 322–30
half life 325–28
intact cells 323–25
methods 322, 323
vesicle polypeptides 295–98
Photoaffinity probes
coupling efficiency 330
N-formyl peptide receptor development 334–39
prospects 346, 347
Photoaffinity reagents
azido-AMP, azido-ATP 294, 295
design 209–11

Ranitidine
drug interactions 130, 131
oxidative metabolism 129, 130

Receptor
dualism 360–63
excited state hypothesis 370–76
application 374–76
receptor–agonist dual state (AIDS) model 363–70
bifunctional 366–70
receptor–agonist interaction kinetics 359, 360
spent 353, 364
transition states 371
Receptors, angiotensin 349–79
bioactivity 355–59
bioassay 351
desensitization 351, 352
excitation 371
high affinity 364
isolation 376, 377
low affinity 365
model 366–70
molecular model 373
photoaffinity labeling 376, 377
photoprobe 350
Receptors, N-formyl peptide
internalization 345, 346
photoaffinity labeling 333–47
photoaffinity ligands 334–39
structures 334, 335, 337
physicochemical characteristics 342–44
solubilization 339–42
structural characteristics 344, 345
Receptors, thyroid hormone
chemical affinity labeling 328–30
half-life 319, 320
photoaffinity labeling 322–30
properties, chromatin 318, 319
synthetic rates 320–22
Recombinant DNA, drug metabolism
polymorphisms 11–15
Rifampicin
dose 205, 206
enzyme induction 201–204
renal transport 205–207
serum levels 202

Selenium
deficiency 303–306
dietary and ethane production 308
selenium-dependent glutathione peroxidase 307, 308
supranutritional effects 309, 310
and xenobiotic toxicity 303–13
effects in mouse 313
Serum enzyme, anticonvulsant interactions 142, 143
Skeletal muscle, ethanol effects 443–46
Slow-acting antirheumatic drugs (SAARDs) 384
Smokers
cytochrome P-450 monooxygenase 91
drug-metabolizing enzymes 90, 98, 102
enzyme induction and inhibition 115–17
Solvent abuse
clinical features 456
complications 457, 458
drug abuse 461
epidemiology 453, 454
management 462–66
community 464–66
medical 462
psychological 463, 464
pharmacology 451
psychiatric aspects 459–61
solvents 450, 451

sudden death 459
toxicity 452, 453
Solvent abusers 454–56
classification 454
Stereospecificity, enzyme induction 79
Sulmazole structure 5
Synaptic vesicles
ATP role 299
photoaffinity labeling 295–98
polypeptide features 297, 298
preparation, Torpedo 293, 294
purification 294

Tetrachlorodibenzo(p)dioxin (TCDD)
induction mechanism 4, 5
P_1-450 regulation 13
Theophylline, omperazole interaction 135
Tobacco smoke, non-volatile compounds 91
Tumor
aminopyrene *N*-demethylation 187–90
growth inhibition 92
Tunicamycin structure and viral oligosaccharides 237, 238

UDP-glucuronyl transferases
induction and inhibition 23–26
substrate specificity 24

Vasopressin
photoaffinity labeling 209–17
structure 211
Virus
glycoproteins 221–72 *see also* glycoproteins, oligosaccharides
membrane glycoproteins 251
multiplication, glycosylation inhibitors 250
DNA 262–70
herpes simplex 263–69
herpesvirus 269
influenza A 252–56
inhibitors 250
mouse hepatitis 259–61
retrovirus 260–62
RNA 251–62
Sindbis 258, 259
vesicular stomatitis 256–58
Vitamins, anticonvulsant interaction 139, 140
Vitamin E
deficiency
cytochrome P-450 185
hepatocytes and glutathione 180, 181
hydroperoxide metabolism 178–85
and selenium effects 304, 305

Xenobiotic toxicity and selenium 303–13
mechanisms 310–12